Early intervention in plaque psoriasis: is bimekizumab able to delay chronic inflammation? Prospective multicenter interventional study
Key facts
- Where
- Grenoble Cedex 9, Lyon Cedex 03, Marseille, Martigues, Nice, St Etienne Cedex 2, Toulon és Villeurbanne Cedex, FranciaországSee the 8 sites
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Franciaország
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranciaországTaking people
- Hospital Edouard HerriotLyon Cedex 03, FranciaországTaking people
- Hôpital Saint JosephMarseille, FranciaországTaking people
- Du Docteur Ruer S.E.L.A.R.L.Martigues, FranciaországTaking people
- Centre Hospitalier Universitaire de NiceNice, FranciaországTaking people
- Centre Hospitalier Universitaire De Saint EtienneSt Etienne Cedex 2, FranciaországTaking people
- Centre Hospitalier Intercommunal Toulon / La Seine-Sur-MerToulon, FranciaországTaking people
- Medipole Hopital PriveVilleurbanne Cedex, FranciaországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire De Nice
- Trial code
- EU 2024-514647-29-01
- Record updated
- 2026. augusztus 5.
- Original description
To compare efficacy of bimekizumab versus topical corticosteroids on psoriasis clinical disease activity, assessed by PGA, at week 16 and week 24.Read full original descriptionShow less
EARLYPSO Early intervention in plaque psoriasis: is bimekizumab able to delay chronic inflammation? Prospective multicenter interventional study
To compare efficacy of bimekizumab versus topical corticosteroids on psoriasis clinical disease activity, assessed by PGA, at week 16 and week 24.
Inclusion: Men and women; Patient willing and able to attend all study visits; ≥ 18 and <45 years; Plaque psoriasis without psoriatic arthritis; Patients with mild psoriasis PASI >2 and <6; Patient with at least one lesion on the elbows, the knees, or the lower back (additional lesions in other areas on top are allowed); Disease duration less than 6 months (short duration psoriasis) or >2 years (long duration psoriasis); For women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed; Affiliation to a social security system; Signed informed consent.
Exclusion: Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation; Any contraindication to bimekizumab or topical steroids, including but not limited to history of cancer<5 years, active infection, latent tuberculosis; Pregnant or breast-feeding women. Or women with potential childbearing and not taking contraceptives or who plan to get pregnant during the study duration; Non plaque psoriasis; Vulnerable people: minors, adult under guardianship or deprived of freedom.